Infection Prevention and Control Implications of Special Pathogens in Children.

Ebola High-consequence infectious diseases Infection control Infection prevention Marburg Mpox Preparedness Special pathogen

Journal

Pediatric clinics of North America
ISSN: 1557-8240
Titre abrégé: Pediatr Clin North Am
Pays: United States
ID NLM: 0401126

Informations de publication

Date de publication:
Jun 2024
Historique:
medline: 17 5 2024
pubmed: 17 5 2024
entrez: 16 5 2024
Statut: ppublish

Résumé

Special pathogens are broadly defined as highly transmissible organisms capable of causing severe disease in humans. Children's hospital healthcare personnel (HCP) should be prepared to identify patients possibly infected with a special pathogen, isolate the patient to minimize transmission, and inform key infection prevention, clinical, and public health stakeholders. Effective preparedness requires resources and practice with attention to education, policies and procedures, drills and training, and supplies. Successfully preparing for special pathogens is an important measure toward keeping communities, HCP, and patients and families safe in this global age that brings pathogens from across the world to our doorstep.

Identifiants

pubmed: 38754934
pii: S0031-3955(24)00025-7
doi: 10.1016/j.pcl.2024.01.014
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

431-454

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure L.K. Kociolek reports grant support from Merck, United States and the Department of Health and Human Services, United States, Health Resources and Services Administration, United States. A.L. Shane reports grant support from the Department of Health and Human Services, Administration for Strategic Preparedness and Response, United States (BARDA). K.A. Simonsen reports grant support from Merck, Alinta, and the Department of Health and Human Services, Administration for Strategic Preparedness and Response to support her salary. D.M. Zerr reports grant from Merck and consultancy for Allovir.

Auteurs

Larry K Kociolek (LK)

Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, 225 East Chicago Avenue, Box 20, Chicago, IL 60611, USA. Electronic address: Lkociolek@luriechildrens.org.

Andi L Shane (AL)

Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Emory Children's Center, 2015 Uppergate Drive Northeast, Room 504A, Atlanta, GA 30322, USA.

Kari A Simonsen (KA)

Department of Pediatrics, University of Nebraska Medical Center, 982162 Nebraska Medical Center, Omaha, NE 68198, USA.

Danielle M Zerr (DM)

Department of Pediatrics, University of Washington, Seattle Children's Hospital, Mailstop MA7.226, 4800 Sand Point Way, Seattle, WA 98105, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH